NCT05353972View on ClinicalTrials.gov

Evaluate IMG-007 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions

Healthy Participants

Interventions

DRUG

IMG-007 or placebo

intravenously administered

Trial Locations (1)

6009

Linear Clinical Research, Nedlands

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Inmagene LLC

INDUSTRY

NCT05353972 - Evaluate IMG-007 in Healthy Participants | Biotech Hunter | Biotech Hunter